NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

This trial is testing an oral drug called NBM-BMX for two groups: people with advanced solid tumors that no longer respond to standard treatments, and people who have been newly diagnosed with glioblastoma (an aggressive brain tumor). The study is in an early phase to assess safety and determine the right dose. **You may be eligible if...** - You are over 18 - Group A: You have advanced solid tumors that have stopped responding to standard therapies, or no standard therapy is available - Group B: You have newly diagnosed glioblastoma (brain tumor) - You have at least one measurable tumor on imaging - You are in reasonably good health (ECOG 0–2) - Your liver, kidney, and blood function are within acceptable limits - Your heart rhythm is normal (QTcF ≤480ms) **You may NOT be eligible if...** - Your organ function is significantly impaired - You recently received blood transfusions to meet eligibility criteria - You are unable to comply with study visit requirements - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.